The Wegovy Pill Is Now Available, but There’s 1 Big Catch Patients Need to Know

Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic ...
Healio

Ozempic tied to decrease in total daily insulin dose for adults with type 1 diabetes

Once-weekly semaglutide 1 mg was tied to a reduction in total daily insulin dose among adults with type 1 diabetes, ...
WebMD

How the New GLP-1 Weight Loss Pill Compares to the Shot

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?
KTLA

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 5, 2025 /PRNewswire/ -- Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to ...

Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
Morningstar

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

PLAINSBORO, N.J., and BAGSVÆRD, Denmark, Oct. 20, 2025 /PRNewswire/ -- Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be presented at ...
European Medical Journal

Semaglutide Reduces Hospital Admissions in Patients with Cardiovascular Disease

Treatment with semaglutide has been shown to reduce the total number of hospital admissions and the duration of stays in patients with established cardiovascular disease (CVD) and overweight or ...